Key result
PE management faces significant unresolved challenges requiring more randomized clinical trials and comprehensive data.
Why the study?
Acute pulmonary embolism is clinically heterogeneous, lacking randomized clinical trials, and many important obstacles in diagnosis, reperfusion, anticoagulation, and subgroup treatment remain unresolved in clinical practice.
There are significant unresolved clinical dilemmas in the management of acute pulmonary embolism, underscoring the need for multidisciplinary approaches and further randomized clinical trials.
Answers are grounded in this paper and cite their sources.
Persistent PE management uncertainties warrant cautious guideline application; leaves open key questions for dedicated randomized trials.
Background. Acute pulmonary embolism (PE) is very heterogeneous disease regarding etiology and clinical presentation. Because of that the treatment of PE need multidisciplinary approach creating locally pulmonary embolism response teams (PERT) to deal with various problems associated with PE management. Review. We try to review some unresolved issues in the management of PE, through the diagnostic, reperfusion, anticoagulation and subgroups treatments. In spite of the recent advancement in oral anticoagulation therapy for venous thromboembolism, risk stratification and diagnosis of chronic thromboembolic pulmonary hypertension, all build in the 2019 European Society of Cardiology guidelines, many important obstacles in PE treatment remained. Unlike acute coronary syndrome, PE field is lacking randomized clinical trials and many important questions are opened in front of everyday practice. Conclusion. There are many unmet needs in PE management and we need a lot of randomized trials or data from large registries to resolve some burning problems in the handling of PE patients.
No takes yet. Share an insight, caveat, or question.
Obradović et al. (2021) conducted a review in Pulmonary embolism. Management of pulmonary embolism was evaluated. Despite recent advancements in oral anticoagulation and risk stratification, the management of pulmonary embolism still faces many unresolved dilemmas and lacks sufficient randomized clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: